

Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patients worldwide

London, 4 June 2026 – Hikma Pharmaceuticals PLC, today published its 2025 Sustainability Report – Acting Responsibly – reaffirming access to medicine as the cornerstone of its sustainability strategy and its leading sustainability pillar. In 2025, Hikma treated 222 million patients globally, launched 84 new products and invested \$197 million in manufacturing capacity.

The report also provides an update on Hikma's three other sustainability pillars – people, the environment and ethics and governance. On people, the company achieved a 73% employee engagement score and increase in average training hours to 7.9 per employee. On the environment, Hikma reduced Scope 1 and 2 emissions by 18% against its 2020 baseline – on track to achieve its 25% 2030 target – and expanded its renewable energy capacity by 354% since 2021. On ethics and governance, 99% of employees completed Code of Conduct training and 92% of surveyed suppliers demonstrated strong alignment with Hikma's Supplier Code of Conduct.

Tim Brooks, VP Sustainability said: "While access to medicine remains at the heart of our sustainability strategy, by focusing on our four pillars we are supporting the long-term success of our business and delivering on our responsibilities to patients, colleagues, communities and our other stakeholders."

The full report is available at www.hikma.com.

- ENDS -

About Hikma:

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)



Enquiries

Hikma Pharmaceuticals PLC

Hikma (Investors)

Susan Ringdal
EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 (0)7776 477050

FTI Consulting (Media)

Ciara Martin

+44 (0)7779 775979